.png)
Assisted Reproductive Technology has transformed the landscape of infertility treatment, offering hope to countless individuals and couples. As the field continues to evolve, the future of ART looks promising, with the potential to help even more people realize their dream of parenthood.
ART encompasses a variety of medical procedures designed to aid in conception. These techniques involve manipulating eggs, sperm, or embryos to increase the chances of fertilization and pregnancy.
The Growing Demand for ART
The demand for ART has been steadily increasing over the years due to many couples are choosing to delay parenthood, leading to decreased fertility in both men and women. Lifestyle factors such as stress, poor diet, and environmental toxins contribute to higher rates of infertility. Growing awareness about ART and its success rates has encouraged more couples to seek treatment. Continuous advancements in ART techniques have improved success rates and expanded treatment options.
The Assisted reproductive technology (ART) market was valued at USD 23,677.69 million in 2023 and is projected to reach USD 39,093.68 million by 2032.
This article has listed down the global top 5 assisted reproductive technology operating in the market. They are as follows:
Top 5 Companies in the ART Industry
1. Cooper Surgical
Revenue: Approximately $2.6 billion (as of 2023).
Latest Developments: Cooper Surgical is a major player in women's health, with a significant presence in the ART market. The company has a diverse portfolio, including IVF-related products like culture media, embryo transfer devices, and tools for sperm management. Recent developments include acquisitions of ART-focused companies, such as Origio and The Kreate Group, as part of their strategy to expand their portfolio in reproductive medicine. Cooper Surgical has also continued to innovate in the field of genomics and genetic screening, which is transforming the ART landscape.
Merger and Acquisition: Cooper Surgical’ s acquisition of Origio in 2020 expanded its reach in IVF and reproductive health. The company’s strong acquisition strategy has allowed it to grow its presence in the global ART market.
2. Cook Medical
Revenue: Approx. $2.2 billion (2023).
Latest Developments: Cook Medical is involved in a range of medical devices, including those used in ART. Their ART division focuses on devices and tools for reproductive medicine, such as embryo transfer catheters and sperm processing systems. In recent years, Cook Medical has been innovating in embryo cryopreservation and developing new technology to assist IVF procedures, improving patient outcomes.
Merger and Acquisition: While Cook Medical is more known for its broad medical device portfolio, it has made acquisitions in the reproductive technology space, specifically in tools related to infertility treatments. Cook is also known for its ongoing investments in research to innovate in reproductive health.
3. Irvine Scientific
Revenue: Estimated $300 million (2023).
Latest Developments: Irvine Scientific is a leader in ART, specializing in cell culture media, embryo culture products, and tools that optimize embryo growth during IVF. The company is dedicated to developing high-quality, scientifically advanced products for IVF clinics worldwide. One of their key innovations is the development of chemically defined culture media that reduce variability and enhance the chances of embryo survival.
Merger and Acquisition: In 2019, Irvine Scientific was acquired by JX Nippon Chemical Company, a Japanese chemical conglomerate. This acquisition has helped Irvine Scientific expand its research and development capabilities, particularly in the Asian market. The company continues to innovate in the field of cell culture and embryo cryopreservation.
4. Vitro Life
Revenue: Around $450 million (2023).
Latest Developments: Vitrolife is a key player in ART, specializing in providing high-quality culture media, incubators, and cryopreservation products used during IVF treatments. The company has been expanding its focus on developing advanced technologies for embryo culture and genetic screening. A significant development in recent years is Vitrolife's efforts to improve embryo freezing technology and the launch of novel products for gene editing and embryo diagnostics, which hold promise in improving IVF success rates.
Merger and Acquisition: In 2021, Vitrolife acquired The Kreate Group, a provider of embryo culture media and IVF equipment. This acquisition strengthened Vitrolife's position in the global ART market, particularly in Europe and Asia, allowing the company to integrate complementary products into its portfolio.
5. Origio (part of CooperSurgical)
Revenue: Estimated at $100–150 million (pre-acquisition by CooperSurgical).
Latest Developments: Origio, which is now part of CooperSurgical, focuses on providing ART-related consumables, such as culture media, sperm processing systems, and embryo cryopreservation tools. Before its acquisition, Origio was expanding its product portfolio with cutting-edge technologies for IVF clinics, including improved embryo freezing systems and genetic screening technologies. Since joining CooperSurgical, it has been integrated into the larger company’s global ART offerings.
Merger and Acquisition: As mentioned earlier, Origio was acquired by CooperSurgical in 2020. This acquisition was part of CooperSurgical’s strategy to expand its leadership position in the global ART market.
The Future of ART
The future of ART holds immense promise. Researchers are continually exploring new techniques and technologies to improve success rates and patient experience.
Advanced genetic screening techniques allow for the selection of healthy embryos, reducing the risk of genetic disorders. AI-powered tools can analyze vast amounts of data to optimize treatment plans and predict outcomes. Stem cell research holds the potential to revolutionize fertility treatment by generating eggs and sperm from stem cells.
While ART offers hope to many, it's important to approach it with realistic expectations and consult with qualified fertility specialists. By understanding the risks, benefits, and limitations of different ART procedures, couples can make informed decisions about their family-building journey.